Activation of the renin–angiotensin system may be involved in the development of hepatic steatosis, a condition that is associated with insulin resistance. We showed that in rats, angiotensin II induced accumulation of triglycerides in the renal tubular and cardiac cells, although it significantly reduced the weight of the rats. Here we investigated the liver lipid content of rats given long-term angiotensin II administration. Angiotensin II (0.7 mg/kg/day) was infused into the rats for 7 days via an osmotic minipump. Some rats also received hydralazine or losartan concomitantly. It was shown that angiotensin II reduced oil red O-stainable lipid droplets (6% of the control value) and liver triglyceride content (angiotensin II: 4.6 ± 0.8 µg/mg, control: 11.7 ± 1.1 µg/mg). Both of these phenomena were blocked by losartan, but not by hydralazine. Angiotensin II infusion reduced the expression and activity of AMP-activated protein kinase. In addition, angiotensin II decreased the mRNA expression of peroxisome proliferator-activated receptor-α and genes related to β-oxidation, although mRNA expression of genes related to lipogenesis were not affected. Angiotensin II reduced triglyceride content in the liver, unlike in the kidney or heart, via an AT1 receptor-dependent mechanism.
BatallerRGabeleEParsonsCJ. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology2005; 41: 1046–1055.
2.
PaizisGGilbertRECooperME. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol2001; 35: 376–385.
3.
ToxUSteffenHM. Impact of inhibitors of the renin–angiotensin–aldosterone system on liver fibrosis and portal hypertension. Curr Med Chem2006; 13: 3649–3661.
4.
HiroseAOnoMSaibaraT. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology2007; 45: 1375–1381.
5.
IshizakaNSaitoKNoiriE. Administration of ANG II induces iron deposition and upregulation of TGF-beta1 mRNA in the rat liver. Am J Physiol Regul Integr Comp Physiol2005; 288: R1063–R1070.
6.
DixonJBBhathalPSO’BrienPE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology2001; 121: 91–100.
7.
LeandroGMangiaAHuiJ. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology2006; 130: 1636–1642.
8.
PaisRPascaleAFedchuckLCharlotteFPoynardTRatziuV. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Gastroenterol Clin Biol2010: in press.
9.
YoshijiHNoguchiRIkenakaY. Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res Notes2009; 2: 70.
10.
UekiMKodaMShimizuTMitsutaAYamamotoTMurawakiY. Effect of an angiotensin-II type-1 receptor blocker, candesartan on hepatic fibrosis in chronic hepatitis C: a prospective study. Hepatogastroenterology2009; 56: 1100–1104.
11.
YamaguchiKYangLMcCallS. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology2007; 45: 1366–1374.
12.
SaitoKIshizakaNHaraM. Lipid accumulation and transforming growth factor-beta upregulation in the kidneys of rats administered angiotensin II. Hypertension2005; 46: 1180–1185.
13.
HongoMIshizakaNFurutaK. Administration of angiotensin II, but not catecholamines, induces accumulation of lipids in the rat heart. Eur J Pharmacol2009; 604: 87–92.
14.
IshizakaNMatsuzakiGSaitoKNoiriEMoriINagaiR. Expression and localization of PDGF-B, PDGF-D, and PDGF receptor in the kidney of angiotensin II-infused rat. Lab Invest2006; 86: 1285–1292.
15.
IshizakaNde LeonHLaursenJB. Angiotensin II-induced hypertension increases heme oxygenase-1 expression in rat aorta. Circulation1997; 96: 1923–1929.
16.
IshizakaNAizawaTYamazakiI. Abnormal iron deposition in renal cells in the rat with chronic angiotensin II administration. Lab Invest2002; 82: 87–96.
17.
AizawaTIshizakaNTaguchiJ. Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats: possible role in renoprotection. Hypertension2000; 35: 800–806.
18.
HongoMIshizakaNFurutaK. Administration of angiotensin II, but not catecholamines, induces accumulation of lipids in the rat heart. Eur J Pharmacol2008; 604: 87–92.
19.
OhnoTHorioFTanakaSTeradaMNamikawaTKitohJ. Fatty liver and hyperlipidemia in IDDM (insulin-dependent diabetes mellitus) of streptozotocin-treated shrews. Life Sci2000; 66: 125–131.
20.
SunLHalaihelNZhangWRogersTLeviM. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem2002; 277: 18919–18927.
21.
UenoMSuzukiJZenimaruY. Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice. Am J Physiol Endocrinol Metab2008; 294: E1109–E1118.
22.
YuBCChangCKOuHYChengKCChengJT. Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats. Cardiovasc Res2008; 80: 78–87.
23.
MatsuzakaTShimanoHYahagiN. Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice. Diabetes2004; 53: 560–569.
24.
IshizakaNHongoMMatsuzakiG. Effects of the AT(1) receptor blocker losartan and the calcium channel blocker benidipine on the accumulation of lipids in the kidney of a rat model of metabolic syndrome. Hypertens Res2010; 33: 263–268.
25.
ViolletBForetzMGuigasB. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol2006; 574: 41–53.
26.
YangJMaikaSCraddockLKingJALiuZM. Chronic activation of AMP-activated protein kinase-alpha1 in liver leads to decreased adiposity in mice. Biochem Biophys Res Commun2008; 370: 248–253.
27.
Hagstrom-ToftEThorneAReynisdottirS. Evidence for a major role of skeletal muscle lipolysis in the regulation of lipid oxidation during caloric restriction in vivo. Diabetes2001; 50: 1604–1611.
28.
van der MeerRWHammerSSmitJW. Short-term caloric restriction induces accumulation of myocardial triglycerides and decreases left ventricular diastolic function in healthy subjects. Diabetes2007; 56: 2849–2853.
29.
HammerSvan der MeerRWLambHJ. Progressive caloric restriction induces dose-dependent changes in myocardial triglyceride content and diastolic function in healthy men. J Clin Endocrinol Metab2008; 93: 497–503.
30.
BrinkMWellenJDelafontaineP. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest1996; 97: 2509–2516.
31.
BrinkMPriceSRChrastJ. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Endocrinology2001; 142: 1489–1496.
CabassiACoghiPGovoniP. Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat. J Clin Endocrinol Metab2005; 90: 2888–2897.
34.
KatherHWielandEFischerBWirthASchlierfG. Adrenergic regulation of lipolysis in abdominal adipocytes of obese subjects during caloric restriction: reversal of catecholamine action caused by relief of endogenous inhibition. Eur J Clin Invest1985; 15: 30–37.
35.
DuJPengTScheideggerKJDelafontaineP. Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism. Arterioscler Thromb Vasc Biol1999; 19: 2119–2126.
36.
MaYZhangLPengT. Angiotensin II stimulates transcription of insulin-like growth factor I receptor in vascular smooth muscle cells: role of nuclear factor-kappaB. Endocrinology2006; 147: 1256–1263.
37.
IshizakaNAlexanderRWLaursenJB. G protein-coupled receptor kinase 5 in cultured vascular smooth muscle cells and rat aorta. Regulation by angiotensin II and hypertension. J Biol Chem1997; 272: 32482–32488.
38.
ToblliJEMunozMCCaoGMellaJPereyraLMastaiR. ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring)2008; 16: 770–776.
39.
FujitaKYonedaMWadaK. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig Dis Sci2007; 52: 3455–3464.
40.
YamamotoEDongYFKataokaK. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension2008; 52: 573–580.
41.
RanJHiranoTAdachiM. Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Am J Physiol Endocrinol Metab2004; 287: E955–961.
42.
RanJHiranoTAdachiM. Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats. J Hypertens2005; 23: 1525–1530.
43.
WeiYClarkSEMorrisEM. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol2008.
44.
WeiYClarkSEThyfaultJP. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. Am J Pathol2009; 174: 1329–1337.
45.
HuisamenBPerelSJFriedrichSOSalieRStrijdomHLochnerA. ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance. Mol Cell Biochem2011; 349: 21–31.
46.
OgiharaTAsanoTAndoK. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension2002; 40: 872–879.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
